Creating a tumor bank for families with multiple blood cancers
Official title: Establishing a Tumor Bank and Initial Analysis of Germline and Tumor-Related Genetic Alterations in Families With Multiple Lymphoproliferative Malignancies
Run by Dana-Farber Cancer Institute · NCT00131014 · Data updated 2026-11-12
This study is trying to collect samples from families with multiple blood cancers to see if there are specific genetic factors that make them more likely to develop lymphomas.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1500 (estimated) |
| Sponsor | Dana-Farber Cancer Institute Academic / other |
| Locations | 1 site (Boston, Massachusetts) |
| Status | Recruiting |
| Started | August 9, 2004 |
| Main results expected | January 2033 |
| Study ends | January 2033 |
| Registry record updated | October 13, 2026 |
| Trial ID | NCT00131014 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals diagnosed with non-Hodgkin's lymphoma, Hodgkin's disease, or chronic lymphocytic leukemia who have a first-degree relative with a lymphoproliferative disorder.
✕Probably not a fit
Patients without a family history of lymphoproliferative disorders or those not diagnosed with the specified conditions may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to explore genetic factors that may contribute to the development of lymphomas by establishing a tumor bank. Participants will provide detailed family and medical histories, along with blood and possibly mouthwash samples, which can be submitted by mail. The study will also involve obtaining consent for the use of lymphoma tissue blocks from participants and their affected relatives. The goal is to identify unique genetic characteristics in familial lymphomas compared to sporadic cases and to pinpoint genes that may increase lymphoma risk.
Why it matters
Potential benefit: If successful, this study could lead to better understanding and potential prevention strategies for lymphoma in families with a history of these cancers.
How similar studies have gone: Other studies have shown success in identifying genetic factors in familial cancers, suggesting this approach may yield valuable insights.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Any individual diagnosed with non-Hodgkin's lymphoma or Hodgkin's disease or chronic lymphocytic leukemia (CLL), who has a 1st degree relative (parent, sibling or child) with a lymphoproliferative disorder; or families in which the individual has a lymphoproliferative disorder, and an unusual clustering of frequent or premature solid tumors is also observed. * Family members of the individual, either affected or unaffected with lymphoma, who are contacted by the individual and agree to participate in the study. * Deceased family members may be included in the study. Public records such as death certificates may be used to confirm the history. Consent for medical records or tissue blocks will be obtained from the deceased family member's next of kin. The hierarchy of relatives defined as next of kin is spouse, offspring, parents and siblings. Archived tissue samples may be used for genetic research. * Age \> 18 years Exclusion Criteria: * Subjects without a family history of lymphoma
Where it's running
-
Dana-Farber Cancer Institute
Boston, Massachusetts, United States Recruiting
Study contacts
- Principal investigator: Jennifer R. Brown, MD, PhD — Dana-Farber Cancer Institute
- Study coordinator: Celeste Carey, MS
- Email: celeste_carey@dfci.harvard.edu
- Phone: 857-215-1646
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Collecting and reporting data on patients receiving stem cell transplants
This study is trying to gather and share information about patients getting stem cell transplants for blood cancers to better understand how well these treatments work.
-
Using special T cells to treat EBV-positive lymphoma
This study is testing a new treatment using special T cells to help people with EBV-positive Hodgkin's or non-Hodgkin lymphoma fight their cancer.
-
BEX101 CAR-T at the bedside for relapsed or refractory B-cell NHL
A bedside, on-site CAR-T therapy called BEX101 is being tested in adults with relapsed or refractory B-cell non-Hodgkin’s lymphoma to see if it is safe and can help control the disease.
-
KSVCBD Injection for B-cell Non-Hodgkin's Lymphoma with CD19 and/or BCMA
This study tests KSVCBD, a CAR-T therapy made inside the body, in adults with relapsed or refractory B-cell non-Hodgkin's lymphoma to see if it is safe and can help fight the cancer.
-
Chemogenomic profiling for blood cancers
This project will test whether detailed genetic and molecular profiling of bone marrow, blood, or tissue samples can better characterize diagnosis and relapse for people with suspected or known blood cancers.
-
Multi-omics testing for blood and bone marrow cancers
This project will test a multi-omics lab approach on bone marrow, blood, biopsy and other fluid samples from people with suspected or known hematologic cancers to see if it can better characterize their disease.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.